title: Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet.
abstract: The biopharmaceutics classification system (BCS) allows biowaiver for rapid dissolving immediate-release (IR) products of Class I drugs (high solubility and high permeability). The possibility of extending biowaivers to Class III high solubility and low permeability drugs is currently under scrutiny. In vivo bioequivalence data of different formulations of Class III drugs would support such an extension. The objective of this work was to demonstrate the bioequivalence of two marketed IR tablet products of a Class III drug, metformin hydrochloride, that are rapidly dissolving and have similar in vitro dissolution profiles. The effect of race on the systemic exposure of metformin was also explored. A randomized, open-label, two-period crossover study was conducted in 12 healthy Chinese male volunteers. Each subject received a single-dose of 500 mg of each product after an overnight fasting. The plasma concentrations of metformin were followed for 24 h. No significant formulation effect was found for the bioequivalence metrics: areas under concentration-time curve (AUC0-t, AUC0-infinity) and maximal concentration (Cmax). The 90% confidence intervals for the ratio of means were found within the acceptance range of 80-125% for the log-transformed data. Based on these results, it was concluded that the two IR products are bioequivalent. The pharmacokinetic parameters of metformin in Chinese for both products were similar and were in good agreement with those reported for metformin IR tablets in other ethnic populations. This study serves as an example for supporting biowaiver for BCS Class III drugs.
authors.affiliation: Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan.
authors.forename: Ching-Ling
authors.initials: CL
authors.lastname: Cheng
authors.forename: Lawrence X
authors.initials: LX
authors.lastname: Yu
authors.forename: Hwei-Ling
authors.initials: HL
authors.lastname: Lee
authors.forename: Chyun-Yu
authors.initials: CY
authors.lastname: Yang
authors.forename: Chang-Sha
authors.initials: CS
authors.lastname: Lue
authors.forename: Chen-Hsi
authors.initials: CH
authors.lastname: Chou
mesh_terms: D000328:Adult; D044466:Asian People; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008687:Metformin / Q000493:pharmacokinetics*; D010539:Permeability; D012995:Solubility; D013607:Tablets; D013810:Therapeutic Equivalency; D013997:Time Factors
chemical_list: D007004:Hypoglycemic Agents; D013607:Tablets; D008687:Metformin